로딩 중…
지수 로딩 중…
Cellid, Co., Ltd.
299660· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,760+5.34%
2026-06-19
Price Chart
Cellid, Co., Ltd.-52.50%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 81.43B KRW |
| Revenue | 10.48B KRW |
| Net Income | -10.87B KRW |
| Total Assets | 114.94B KRW |
| Net Assets | 72.69B KRW |
| Employees | 56 |
| Value | |
| P/B | 1.12x |
| P/S | 7.77x |
| FCF Yield | -28.28% |
| Profitability | |
| ROE | -14.95% |
| ROA | -9.46% |
| Op. Margin | -97.82% |
| Revenue Growth | 104.39% |
| Financial Health | |
| Debt Ratio | 58.12% |
| Total Debt | 29.38B KRW |
| FCF | -23.03B KRW |
| Cash | 10.53B KRW |
| Current Ratio | 0.66x |
| Performance | |
| 1Y Return | -52.50% |
| 1M Return | -11.82% |
| From 52W High | -61.83% |
| 1Y MDD | -73.96% |
| Trading | |
| Volume | 805,725 shares |
| Foreign Own. | 1.94% |
| Per Share | |
| EPS | -394 KRW |
| BPS | 2,464 KRW |
Company Info
Cellid, a bio-venture established in 2006, expanded its business in 2024 by merging with ForBaker Co., Ltd. to establish an e-commerce division. The company develops CeliVax-based anti-cancer immunotherapy vaccines and adenovirus vector-based COVID-19 prophylactic vaccines, while also operating biopharmaceutical contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) services from its 2020 GMP facility. Its anti-cancer immunotherapy vaccines are undergoing clinical and non-clinical trials, and its Omicron-specific COVID-19 vaccine has completed Phase 3 administration. Cellid is headquartered in Gwanak-gu, Seoul.